Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.86 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23483863 | 0.93 | OPRM1 (1.00) | OPRM1OPRD1NOD2NOD1MAPT | |
| SCHEMBL15413322 | 0.89 | OPRM1 (0.94) | OPRM1OPRD1NOD2NOD1MAPT | |
| SCHEMBL20816042 | 0.87 | OPRM1 (0.65) | OPRM1OPRD1NOD2NOD1TP53 | |
| SCHEMBL20816038 | 0.85 | OPRM1 (0.85) | OPRM1OPRD1NOD2NOD1TP53 | |
| SCHEMBL20830348 | 0.74 | OPRM1 (0.49) | OPRM1OPRD1GCGRTP53MAPT | |
| SCHEMBL20816040 | 0.73 | OPRM1 (0.48) | OPRM1OPRD1NOD2NOD1GCGR | |
| SCHEMBL20816045 | 0.65 | LMNA (0.47) | OPRM1OPRD1NOD2NOD1TP53 | |
| SCHEMBL25015538 | 0.65 | OPRM1 (0.57) | OPRM1OPRD1MAPTMEN1KMT2A | |
| SCHEMBL16486105 | 0.62 | NOD2 (0.58) | NOD2NOD1PTGS2 | |
| SCHEMBL21901813 | 0.62 | TSHR (0.54) | MAPTMEN1KMT2AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340127-A1 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY INHIBITION OF FBXO44 | Sanford Burnham Prebys Medical Discovery Institute | 2023-10-26 | — | — | US | claimed |
| US-20230340127-A1 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY INHIBITION OF FBXO44 | Sanford Burnham Prebys Medical Discovery Institute | 2023-10-26 | — | — | US | disclosed |
| US-10577371-B2 | Small molecule histone methyltransferase SUV39H1 inhibitor and uses thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190084987-A1 | Small Molecule Histone Methyltransferase SUV39H1 Inhibitor and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577371-B2 | Small molecule histone methyltransferase SUV39H1 inhibitor and uses thereof | SUV39H2, SUV39H1, EZH1 | OPRM1 4500/4885OPRD1 4790/4885NOD2 2651/4885 |
| US-20190084987-A1 | Small Molecule Histone Methyltransferase SUV39H1 Inhibitor and Uses Thereof | SUV39H2, SUV39H1, EZH1 | OPRM1 4500/4885OPRD1 4790/4885NOD2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.